Skip to main content
Top
Published in: BMC Cancer 1/2015

Open Access 01-12-2015 | Research article

Ascorbic acid and ascorbate-2-phosphate decrease HIF activity and malignant properties of human melanoma cells

Authors: Sarah L. Miles, Adam P. Fischer, Sandeep J. Joshi, Richard M. Niles

Published in: BMC Cancer | Issue 1/2015

Login to get access

Abstract

Background

Hypoxia inducible factor-1 alpha (HIF-1α) is thought to play a role in melanoma carcinogenesis. Posttranslational regulation of HIF-1α is dependent on Prolyl hydroxylase (PHD 1–3) and Factor Inhibiting HIF (FIH) hydroxylase enzymes, which require ascorbic acid as a co-factor for optimal function. Depleted intra-tumoral ascorbic acid may thus play a role in the loss of HIF-1α regulation in melanoma. These studies assess the ability of ascorbic acid to reduce HIF-1α protein and transcriptional activity in metastatic melanoma and reduce its invasive potential.

Methods

HIF-1α protein was evaluated by western blot, while transcriptional activity was measured by HIF-1 HRE-luciferase reporter gene activity. Melanoma cells were treated with ascorbic acid (AA) and ascorbate 2-phosphate (A2P) to assess their ability to reduce HIF-1α accumulation and activity. siRNA was used to deplete cellular PHD2 in order to evaluate this effect on AA’s ability to lower HIF-1α levels. A2P’s effect on invasive activity was measured by the Matrigel invasion assay. Data was analyzed by One-way ANOVA with Tukey’s multiple comparisons test, or Student-T test as appropriate, with p < .05 considered significant.

Results

Supplementation with both AA and A2P antagonized normoxic as well as cobalt chloride- and PHD inhibitor ethyl 3, 4-dihydroxybenzoate induced HIF-1α protein stabilization and transcriptional activity. Knockdown of the PHD2 isoform with siRNA did not impede the ability of AA to reduce normoxic HIF-1α protein. Additionally, reducing HIF-1α levels with A2P resulted in a significant reduction in the ability of the melanoma cells to invade through Matrigel.

Conclusion

These studies suggest a positive role for AA in regulating HIF-1α in melanoma by demonstrating that supplementation with either AA, or its oxidation-resistant analog A2P, effectively reduces HIF-1α protein and transcriptional activity in metastatic melanoma cells. Our data, while supporting the function of AA as a necessary cofactor for PHD and likely FIH activity, also suggests a potential non-PHD/FIH role for AA in HIF-1α regulation by its continued ability to reduce HIF-1α in the presence of PHD inhibition. The use of the oxidation-resistant AA analog, A2P, to reduce the ability of HIF-1α to promote malignant progression in melanoma cells and enhance their response to therapy warrants further investigation.
Literature
2.
4.
go back to reference Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res. 2000;19(1):21–34.PubMed Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res. 2000;19(1):21–34.PubMed
5.
go back to reference Berrocal A, Cabanas L, Espinosa E, Fernandez-de-Misa R, Martin-Algarra S, Martinez-Cedres JC et al. Melanoma: Diagnosis, Staging, and Treatment. Consensus group recommendations. Advances in therapy. 2014. doi:10.1007/s12325-014-0148-2 Berrocal A, Cabanas L, Espinosa E, Fernandez-de-Misa R, Martin-Algarra S, Martinez-Cedres JC et al. Melanoma: Diagnosis, Staging, and Treatment. Consensus group recommendations. Advances in therapy. 2014. doi:10.1007/s12325-014-0148-2
6.
go back to reference Atkins MB, Gollob JA, Sosman JA, McDermott DF, Tutin L, Sorokin P, et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. Clin Cancer Res. 2002;8(10):3075–81.PubMed Atkins MB, Gollob JA, Sosman JA, McDermott DF, Tutin L, Sorokin P, et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. Clin Cancer Res. 2002;8(10):3075–81.PubMed
9.
go back to reference Satyamoorthy K, Herlyn M. Cellular and molecular biology of human melanoma. Cancer Biol Ther. 2002;1(1):14–7.CrossRefPubMed Satyamoorthy K, Herlyn M. Cellular and molecular biology of human melanoma. Cancer Biol Ther. 2002;1(1):14–7.CrossRefPubMed
12.
go back to reference Kallio PJ, Pongratz I, Gradin K, McGuire J, Poellinger L. Activation of hypoxia-inducible factor 1alpha: posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor. Proc Natl Acad Sci U S A. 1997;94(11):5667–72.CrossRefPubMedPubMedCentral Kallio PJ, Pongratz I, Gradin K, McGuire J, Poellinger L. Activation of hypoxia-inducible factor 1alpha: posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor. Proc Natl Acad Sci U S A. 1997;94(11):5667–72.CrossRefPubMedPubMedCentral
13.
14.
go back to reference Jiang H, Feng Y. Hypoxia-inducible factor 1alpha (HIF-1alpha) correlated with tumor growth and apoptosis in ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2006;16 Suppl 1:405-12. doi:10.1111/j.1525-1438.2006.00310.x.CrossRef Jiang H, Feng Y. Hypoxia-inducible factor 1alpha (HIF-1alpha) correlated with tumor growth and apoptosis in ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2006;16 Suppl 1:405-12. doi:10.​1111/​j.​1525-1438.​2006.​00310.​x.CrossRef
16.
go back to reference Nam SY, Ko YS, Jung J, Yoon J, Kim YH, Choi YJ et al. A hypoxia-dependent upregulation of hypoxia-inducible factor-1 by nuclear factor-kappaB promotes gastric tumour growth and angiogenesis. British journal of cancer. 2011;104(1):166-74. doi:10.1038/sj.bjc.6606020.CrossRefPubMed Nam SY, Ko YS, Jung J, Yoon J, Kim YH, Choi YJ et al. A hypoxia-dependent upregulation of hypoxia-inducible factor-1 by nuclear factor-kappaB promotes gastric tumour growth and angiogenesis. British journal of cancer. 2011;104(1):166-74. doi:10.​1038/​sj.​bjc.​6606020.CrossRefPubMed
17.
go back to reference Semenza GL. Involvement of hypoxia-inducible factor 1 in human cancer. Internal medicine (Tokyo, Japan). 2002;41(2):79–83. Semenza GL. Involvement of hypoxia-inducible factor 1 in human cancer. Internal medicine (Tokyo, Japan). 2002;41(2):79–83.
18.
19.
go back to reference Giatromanolaki A, Sivridis E, Kouskoukis C, Gatter KC, Harris AL, Koukourakis MI. Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma research. 2003;13(5):493-501. doi:10.1097/01.cmr.0000056268.56735.4c.CrossRefPubMed Giatromanolaki A, Sivridis E, Kouskoukis C, Gatter KC, Harris AL, Koukourakis MI. Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma research. 2003;13(5):493-501. doi:10.​1097/​01.​cmr.​0000056268.​56735.​4c.CrossRefPubMed
23.
go back to reference Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer research. 1999;59(22):5830–5.PubMed Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer research. 1999;59(22):5830–5.PubMed
24.
go back to reference Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene. 2000;19(48):5435-43. doi:10.1038/sj.onc.1203938.CrossRefPubMed Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene. 2000;19(48):5435-43. doi:10.​1038/​sj.​onc.​1203938.CrossRefPubMed
28.
go back to reference Kuiper C, Dachs GU, Munn D, Currie MJ, Robinson BA, Pearson JF et al. Increased Tumor Ascorbate is Associated with Extended Disease-Free Survival and Decreased Hypoxia-Inducible Factor-1 Activation in Human Colorectal Cancer. Frontiers in oncology. 2014;4:10. doi:10.3389/fonc.2014.00010.PubMedPubMedCentral Kuiper C, Dachs GU, Munn D, Currie MJ, Robinson BA, Pearson JF et al. Increased Tumor Ascorbate is Associated with Extended Disease-Free Survival and Decreased Hypoxia-Inducible Factor-1 Activation in Human Colorectal Cancer. Frontiers in oncology. 2014;4:10. doi:10.​3389/​fonc.​2014.​00010.PubMedPubMedCentral
29.
go back to reference Kuiper C, Molenaar IG, Dachs GU, Currie MJ, Sykes PH, Vissers MC. Low ascorbate levels are associated with increased hypoxia-inducible factor-1 activity and an aggressive tumor phenotype in endometrial cancer. Cancer research. 2010;70(14):5749-58. doi:10.1158/0008-5472.can-10-0263.CrossRefPubMed Kuiper C, Molenaar IG, Dachs GU, Currie MJ, Sykes PH, Vissers MC. Low ascorbate levels are associated with increased hypoxia-inducible factor-1 activity and an aggressive tumor phenotype in endometrial cancer. Cancer research. 2010;70(14):5749-58. doi:10.​1158/​0008-5472.​can-10-0263.CrossRefPubMed
30.
go back to reference Skrzydlewska E, Sulkowski S, Koda M, Zalewski B, Kanczuga-Koda L, Sulkowska M. Lipid peroxidation and antioxidant status in colorectal cancer. World journal of gastroenterology: WJG. 2005;11(3):403–6.CrossRefPubMedPubMedCentral Skrzydlewska E, Sulkowski S, Koda M, Zalewski B, Kanczuga-Koda L, Sulkowska M. Lipid peroxidation and antioxidant status in colorectal cancer. World journal of gastroenterology: WJG. 2005;11(3):403–6.CrossRefPubMedPubMedCentral
31.
go back to reference Schleich T, Rodemeister S, Venturelli S, Sinnberg T, Garbe C, Busch C. Decreased plasma ascorbate levels in stage IV melanoma patients. Metabolism and Nutrition in Oncology. 2013(EFirst). Schleich T, Rodemeister S, Venturelli S, Sinnberg T, Garbe C, Busch C. Decreased plasma ascorbate levels in stage IV melanoma patients. Metabolism and Nutrition in Oncology. 2013(EFirst).
33.
go back to reference Yamamoto Y, Yamashita S, Fujisawa A, Kokura S, Yoshikawa T. Oxidative stress in patients with hepatitis, cirrhosis, and hepatoma evaluated by plasma antioxidants. Biochemical and biophysical research communications. 1998;247(1):166-70. doi:10.1006/bbrc.1998.8752.CrossRefPubMed Yamamoto Y, Yamashita S, Fujisawa A, Kokura S, Yoshikawa T. Oxidative stress in patients with hepatitis, cirrhosis, and hepatoma evaluated by plasma antioxidants. Biochemical and biophysical research communications. 1998;247(1):166-70. doi:10.​1006/​bbrc.​1998.​8752.CrossRefPubMed
34.
go back to reference Bhagat SS, Ghone RA, Suryakar AN, Hundekar PS. Lipid peroxidation and antioxidant vitamin status in colorectal cancer patients. Indian journal of physiology and pharmacology. 2011;55(1):72–6.PubMed Bhagat SS, Ghone RA, Suryakar AN, Hundekar PS. Lipid peroxidation and antioxidant vitamin status in colorectal cancer patients. Indian journal of physiology and pharmacology. 2011;55(1):72–6.PubMed
35.
go back to reference Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko PW, Dhariwal KR et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proceedings of the National Academy of Sciences of the United States of America. 1996;93(8):3704–9.CrossRefPubMedPubMedCentral Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko PW, Dhariwal KR et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proceedings of the National Academy of Sciences of the United States of America. 1996;93(8):3704–9.CrossRefPubMedPubMedCentral
36.
go back to reference Levine M, Padayatty SJ, Espey MG. Vitamin C: a concentration-function approach yields pharmacology and therapeutic discoveries. Advances in nutrition (Bethesda, Md). 2011;2(2):78-88. doi:10.3945/an.110.000109.CrossRef Levine M, Padayatty SJ, Espey MG. Vitamin C: a concentration-function approach yields pharmacology and therapeutic discoveries. Advances in nutrition (Bethesda, Md). 2011;2(2):78-88. doi:10.​3945/​an.​110.​000109.CrossRef
37.
40.
go back to reference Knowles HJ, Raval RR, Harris AL, Ratcliffe PJ. Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. Cancer Res. 2003;63(8):1764–8.PubMed Knowles HJ, Raval RR, Harris AL, Ratcliffe PJ. Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. Cancer Res. 2003;63(8):1764–8.PubMed
43.
go back to reference Nagao N, Nakayama T, Etoh T, Saiki I, Miwa N. Tumor invasion is inhibited by phosphorylated ascorbate via enrichment of intracellular vitamin C and decreasing of oxidative stress. Journal of cancer research and clinical oncology. 2000;126(9):511–8.CrossRefPubMed Nagao N, Nakayama T, Etoh T, Saiki I, Miwa N. Tumor invasion is inhibited by phosphorylated ascorbate via enrichment of intracellular vitamin C and decreasing of oxidative stress. Journal of cancer research and clinical oncology. 2000;126(9):511–8.CrossRefPubMed
44.
go back to reference Liu JW, Nagao N, Kageyama K, Miwa N. Anti-metastatic effect of an autooxidation-resistant and lipophilic ascorbic acid derivative through inhibition of tumor invasion. Anticancer research. 2000;20(1a):113–8.PubMed Liu JW, Nagao N, Kageyama K, Miwa N. Anti-metastatic effect of an autooxidation-resistant and lipophilic ascorbic acid derivative through inhibition of tumor invasion. Anticancer research. 2000;20(1a):113–8.PubMed
45.
go back to reference Kameyama K, Sakai C, Kondoh S, Yonemoto K, Nishiyama S, Tagawa M et al. Inhibitory effect of magnesium L-ascorbyl-2-phosphate (VC-PMG) on melanogenesis in vitro and in vivo. J Am Acad Dermatol. 1996;34(1):29–33.CrossRefPubMed Kameyama K, Sakai C, Kondoh S, Yonemoto K, Nishiyama S, Tagawa M et al. Inhibitory effect of magnesium L-ascorbyl-2-phosphate (VC-PMG) on melanogenesis in vitro and in vivo. J Am Acad Dermatol. 1996;34(1):29–33.CrossRefPubMed
46.
go back to reference Sasaki T, Majamaa K, Uitto J. Reduction of collagen production in keloid fibroblast cultures by ethyl-3,4-dihydroxybenzoate. Inhibition of prolyl hydroxylase activity as a mechanism of action. The Journal of biological chemistry. 1987;262(19):9397–403.PubMed Sasaki T, Majamaa K, Uitto J. Reduction of collagen production in keloid fibroblast cultures by ethyl-3,4-dihydroxybenzoate. Inhibition of prolyl hydroxylase activity as a mechanism of action. The Journal of biological chemistry. 1987;262(19):9397–403.PubMed
47.
go back to reference Majamaa K, Gunzler V, Hanauske-Abel HM, Myllyla R, Kivirikko KI. Partial identity of the 2-oxoglutarate and ascorbate binding sites of prolyl 4-hydroxylase. The Journal of biological chemistry. 1986;261(17):7819–23.PubMed Majamaa K, Gunzler V, Hanauske-Abel HM, Myllyla R, Kivirikko KI. Partial identity of the 2-oxoglutarate and ascorbate binding sites of prolyl 4-hydroxylase. The Journal of biological chemistry. 1986;261(17):7819–23.PubMed
48.
go back to reference Wang J, Buss JL, Chen G, Ponka P, Pantopoulos K. The prolyl 4-hydroxylase inhibitor ethyl-3,4-dihydroxybenzoate generates effective iron deficiency in cultured cells. FEBS letters. 2002;529(2-3):309–12.CrossRefPubMed Wang J, Buss JL, Chen G, Ponka P, Pantopoulos K. The prolyl 4-hydroxylase inhibitor ethyl-3,4-dihydroxybenzoate generates effective iron deficiency in cultured cells. FEBS letters. 2002;529(2-3):309–12.CrossRefPubMed
51.
go back to reference Metzen E, Berchner-Pfannschmidt U, Stengel P, Marxsen JH, Stolze I, Klinger M et al. Intracellular localisation of human HIF-1 alpha hydroxylases: implications for oxygen sensing. Journal of cell science. 2003;116(Pt 7):1319–26.CrossRefPubMed Metzen E, Berchner-Pfannschmidt U, Stengel P, Marxsen JH, Stolze I, Klinger M et al. Intracellular localisation of human HIF-1 alpha hydroxylases: implications for oxygen sensing. Journal of cell science. 2003;116(Pt 7):1319–26.CrossRefPubMed
52.
go back to reference Malavolti M, Malagoli C, Fiorentini C, Longo C, Farnetani F, Ricci C et al. Association between dietary vitamin C and risk of cutaneous melanoma in a population of Northern Italy. International journal for vitamin and nutrition research Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung Journal international de vitaminologie et de nutrition. 2013;83(5):291-8. doi:10.1024/0300-9831/a000171.CrossRefPubMed Malavolti M, Malagoli C, Fiorentini C, Longo C, Farnetani F, Ricci C et al. Association between dietary vitamin C and risk of cutaneous melanoma in a population of Northern Italy. International journal for vitamin and nutrition research Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung Journal international de vitaminologie et de nutrition. 2013;83(5):291-8. doi:10.​1024/​0300-9831/​a000171.CrossRefPubMed
Metadata
Title
Ascorbic acid and ascorbate-2-phosphate decrease HIF activity and malignant properties of human melanoma cells
Authors
Sarah L. Miles
Adam P. Fischer
Sandeep J. Joshi
Richard M. Niles
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-015-1878-5

Other articles of this Issue 1/2015

BMC Cancer 1/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine